未登录
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏The systemic inflammation response index as a significant predictor of short-term adverse outcomes in acute decompensated heart failure patients: a cohort study from Southern China
Xie, Lin; Wang, Qun; Lu, Hengcheng; Kuang, Maobin; He, Shiming; Xie, Guobo; Sheng, Guotai; Zhang, Shuhua; Wang, Wei; Zou, Yang
分享
收藏Exploratory biomarker analysis of phase III ASTRUM-004 study: Serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancerIII期ASTRUM-004研究探索性生物标志物分析:Serplulimab联合化疗作为晚期鳞状非小细胞肺癌的一线治疗
Zhou, C.; Hu, Y.; Arkania, E.; Kilickap, S.; Ying, K.; Xu, F.; Wu, L.; Wang, X.; Viguro, M.; Makharadze, T.; Guo, L.; Yang, F.; Liu, Y.; Yang, X.; Zhong, S.; Wang, Q.; Li, J.; Shan, Y.; Zhu, J.
分享
收藏HILL: The efficacy and safety of hepatic arterial infusion chemotherapy with FOLFOX regimen combine lenvatinib and durvalumab in unresectable hepatocellular carcinoma: A prospective, phase II, single-armed, clinical trialHILL:FOLFOX方案联合仑伐替尼和度伐利尤单抗经肝动脉灌注化疗在不切除肝细胞癌中的疗效与安全性:一项前瞻性、II期、单臂临床试验
Li, S.; Lu, L.; Wang, Q.; Zhao, R.; Mei, J.; Li, J-B.; Zheng, L.; Wei, W.; Guo, R.
分享
收藏
分享
收藏HLX22 plus HLX02 and XELOX as first-line therapy for HER2positive advanced gastric/gastroesophageal junction cancer: Updated results from a randomized, double-blind phase II study
Li, J.; Gao, Y.; Li, N.; Qiu, M.; Zhang, Y.; Yang, M.; Lu, L.; Li, W.; Ma, Y.; Hou, X.; Sun, G.; Cai, M.; Wang, J.; Lu, J.; Zhong, D.; Yang, F.; Yu, H.; Li, J.; Wang, Q.; Zhu, J.
分享
收藏Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer阿来替尼治疗切除的ALK阳性非小细胞肺癌
Wu, Yi-Long; Dziadziuszko, Rafal; Ahn, Jin Seok; Barlesi, Fabrice; Nishio, Makoto; Lee, Dae Ho; Lee, Jong-Seok; Zhong, Wenzhao; Horinouchi, Hidehito; Mao, Weimin; Hochmair, Maximilian; de Marinis, Filippo; Migliorino, M. Rita; Bondarenko, Igor; Lu, Shun; Wang, Qun; Ochi Lohmann, Tania; Xu, Tingting; Cardona, Andres; Ruf, Thorsten; Noe, Johannes; Solomon, Benjamin J.
分享
收藏